Diafir is a pioneering brand in diagnostic medical and animal products and services. Established in 2011 by a team of renowned researchers from the University of Rennes 1, Diafir has developed the SPID platform. This in-vitro diagnostic medical device, closely connected to the patient, enables rapid diagnosis.

Using their proprietary mid-infrared spectroscopy technology, SPID analyzes the patient's metabolic signature within minutes. This simple, cost-effective, and comprehensive analysis avoids the need for invasive and sometimes painful procedures, helping physicians make quicker diagnoses and reducing healthcare expenses. Currently, Diafir is focused on developing a portfolio of tests for liver and musculoskeletal disorders.

Their primary objectives include validating the NASHMIR in-vitro diagnostic blood test for detecting non-alcoholic steatohepatitis (NASH) and commercializing SYNOFAST, a CE-marked synovial fluid test that assesses the risk of osteoarticular infection within 15 minutes. Stay updated with Diafir's advancements by subscribing to their newsletter or contacting them directly at their Rennes-based address